Gilead­'s Bik­tarvy build its case for long-term use with 4-year da­ta show­ing last­ing HIV sup­pres­sion

Gilead Sci­ences’ dai­ly pill Bik­tarvy has been one of bio­phar­ma’s great suc­cess sto­ries, rid­ing its mar­ket lead­ing HIV ef­fi­ca­cy da­ta to one of the best launch­es on record. Now, set­tling in­to its role as an es­tab­lished brand, Bik­tarvy is sport­ing four-year da­ta that will look to keep pa­tients on board even longer.

Af­ter four years of treat­ment with Bik­tarvy, 98% of HIV pa­tients who had nev­er re­ceived a pri­or an­tivi­ral post­ed vi­ral loads at “un­de­tectable” lev­els with no new re­sis­tance to the drug, ac­cord­ing to da­ta from open-la­bel ex­pan­sions of two Phase III stud­ies pre­sent­ed Sat­ur­day at the vir­tu­al Con­fer­ence on Retro­virus­es and Op­por­tunis­tic In­fec­tions (CROI).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.